Acadia Pharmaceuticals (ACAD) 8-K Update

Governance Change (Item 5.02)

• Effective October 30, 2025, Director Daniel B. Soland resigned from the Board of Directors.
• He also resigned as Chair of the Nominating and Corporate Governance Committee.
• > The filing confirms the departure was not the result of any dispute or disagreement with the Company or the Board.

This report focuses solely on the director departure; no financial metrics or strategic guidance were provided.

Acadia Pharmaceuticals Inc. (ACAD) 8-K Filing Summary

This filing is a Form 8-K (Current Report